Precision BioSciences, Inc.
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
252 articles about Precision BioSciences, Inc.
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/16/2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
3/20/2024
Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.
-
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
3/6/2024
Precision BioSciences, Inc. today announced that its partner iECURE has received approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) for the company’s Clinical Trial Authorization (CTA) application to expand the Phase 1/2 OTC-HOPE study evaluating ECUR-506 into the U.K.
-
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
3/1/2024
Precision BioSciences, Inc. announced that it has agreed to sell to the public by way of an underwritten offering 2,500,000 shares of its common stock and accompanying warrants to purchase up to 2,500,000 shares of common stock at a combined offering price of $16.00 price per share, for total gross proceeds of $40.0 million, before deducting underwriting discounts and commissions.
-
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
2/29/2024
Precision BioSciences, Inc. announced the commencement of a proposed underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers.
-
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
2/20/2024
Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.
-
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
2/14/2024
Precision BioSciences, Inc. announced that the company has received pre-IND regulatory feedback from the U.S. Food and Drug Administration and ex-U.S. agencies.
-
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
2/13/2024
Precision BioSciences, Inc. today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations.
-
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
2/12/2024
Precision BioSciences, Inc. today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.
-
Precision BioSciences to Effect a Reverse Stock Split
2/9/2024
Precision BioSciences, Inc. today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock.
-
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
1/9/2024
Precision BioSciences, Inc. today announced completion of a strategic transaction with TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.
-
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
1/9/2024
TG Therapeutics, Inc. today announced that it has entered into an agreement with Precision BioSciences, Inc. to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
-
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
12/13/2023
Precision BioSciences, Inc. today announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuclease for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.
-
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
12/4/2023
Precision BioSciences, Inc. today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease.”
-
Precision BioSciences to Present at Hep-DART 2023
11/30/2023
Precision BioSciences, Inc. today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
-
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/28/2023
Precision BioSciences, Inc. today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee.
-
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
11/13/2023
Precision BioSciences, Inc. announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ The Liver Meeting being held in Boston, MA.
-
Precision BioSciences to Present at Upcoming Sidoti Conference
11/10/2023
Precision BioSciences, Inc. announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.
-
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
11/9/2023
Precision BioSciences, Inc. today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.